Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucosidase, beta, acid | Starlite/ChEMBL | No references |
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Homo sapiens | synuclein, alpha (non A4 component of amyloid precursor) | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | ubiquitin conjugating enzyme 13 | 0.0239 | 0.7202 | 1 |
Trichomonas vaginalis | ubiquitin-conjugating enzyme E2, putative | 0.0239 | 0.7202 | 0.3197 |
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.0239 | 0.7202 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Trichomonas vaginalis | ubiquitin-conjugating enzyme E2, putative | 0.0239 | 0.7202 | 0.3197 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Onchocerca volvulus | 0.0265 | 0.8186 | 1 | |
Leishmania major | ubiquitin-conjugating enzyme e2, putative | 0.0239 | 0.7202 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.0349 | 0.0349 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Brugia malayi | Ubiquitin conjugating enzyme protein 13 | 0.0239 | 0.7202 | 0.7202 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0349 | 0.0349 |
Loa Loa (eye worm) | ubiquitin conjugating enzyme protein 13 | 0.0239 | 0.7202 | 0.7202 |
Toxoplasma gondii | ubiquitin-conjugating enzyme subfamily protein | 0.0239 | 0.7202 | 0.5 |
Entamoeba histolytica | ubiquitin-conjugating enzyme family protein | 0.0239 | 0.7202 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0216 | 0.631 | 0.1027 |
Trichomonas vaginalis | set domain proteins, putative | 0.0265 | 0.8186 | 0.5589 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0216 | 0.631 | 0.1027 |
Loa Loa (eye worm) | ubiquitin conjugating enzyme protein 13 | 0.0239 | 0.7202 | 0.7202 |
Echinococcus multilocularis | ubiquitin conjugating enzyme E2 N | 0.0239 | 0.7202 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.0349 | 0.0349 |
Echinococcus granulosus | ubiquitin conjugating enzyme E2 N | 0.0239 | 0.7202 | 1 |
Brugia malayi | ubiquitin conjugating enzyme protein 13 | 0.0239 | 0.7202 | 0.7202 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Plasmodium vivax | ubiquitin-conjugating enzyme E2 N, putative | 0.0239 | 0.7202 | 0.5 |
Trypanosoma brucei | ubiquitin-protein ligase, putative | 0.0239 | 0.7202 | 1 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0232 | 0.6955 | 0.6955 |
Brugia malayi | Pre-SET motif family protein | 0.0232 | 0.6955 | 0.6955 |
Loa Loa (eye worm) | O-glycosyl hydrolase family 30 protein | 0.0312 | 1 | 1 |
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.0239 | 0.7202 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Plasmodium falciparum | ubiquitin-conjugating enzyme E2 N, putative | 0.0239 | 0.7202 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.0349 | 0.0349 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1473, AID2293, AID2577, AID2578, AID2587, AID2588, AID2589, AID2590, AID2592, AID2593, AID2595, AID2596, AID2597, AID2613, AID2671, AID488845] | ChEMBL. | No reference |
Potency (functional) | 18.3489 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | ||
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.